Nucleic Acid News and Research

RSS

Basic guides to PCR, labeling neurons featured in Cold Spring Harbor Protocols

Along with new cutting-edge methods, Cold Spring Harbor Protocols is home to an in-depth library of basic laboratory methods.

1 Apr 2009

Jumping genes play significant role in gene regulatory networks

Research performed in the Center for Biomolecular Science & Engineering (CBSE) at the University of California, Santa Cruz, suggests that mobile repetitive elements--also known as transposons or "jumping genes"--do indeed affect the evolution of gene regulatory networks.

16 Feb 2009

Artificial cells, simple model for complex structure

A simple, chemical materials model may lead to a better understanding of the structure and organization of the cell according to a Penn State researcher.

16 Feb 2009

NRL partners with industry to develop compact biosensor for wide-ranging applications

Scientists at the Naval Research Laboratory (NRL) are partnering with industry to develop a sensor system for biomolecules that could make a significant contribution to a variety of fields such as healthcare, veterinary diagnostics, food safety, environmental testing, and national security.

3 Feb 2009

Rare amino acid helps establish how proteins evolve

Three billion years ago, a "new" amino acid was added to the alphabet of 20 that commonly make up proteins in organisms today.

29 Jan 2009

Breakthrough in prenatal screening for Down syndrome

Lenetix, Inc. today announced a significant step in the development of an improved first and second trimester non-invasive fetal chromosomal screening test to detect Down syndrome and other genetic fetal conditions.

29 Jan 2009

Scientists discover key protein component involved in inflammation

Reporting in the journal Nature, researchers led by Emad Alnemri, Ph.D., professor of Biochemistry and Molecular Biology in the Kimmel Cancer Center at Jefferson, discovered a key protein component involved in inflammation.

23 Jan 2009

Discovery of key protein regulator of inflammation and cell death

Reporting in the journal Nature , researchers led by Emad Alnemri, Ph.D., professor of Biochemistry and Molecular Biology in the Kimmel Cancer Center at Jefferson, discovered a key protein component involved in inflammation.

23 Jan 2009

CSL Behring receives FDA approval of RiaSTAP

CSL Behring announced today that the U.S. Food and Drug Administration (FDA) has granted marketing approval for RiaSTAP(TM), the first and only treatment of acute bleeding episodes in patients with congenital fibrinogen deficiency, including afibrinogenemia and hypofibrinogenemia.

19 Jan 2009

Biologically tagged nanowires integrated onto circuit chips

A handheld, ultra-portable device that can recognize and immediately report on a wide variety of environmental or medical compounds may eventually be possible, using a method that incorporates a mixture of biologically tagged nanowires onto integrated circuit chips, according to Penn State researchers.

19 Jan 2009

Microfluidic devices capture and analyze single cancer cells

One of the grand goals in nanotechnology is to develop a single microfluidic device that integrates all of the components needed to perform polymerase chain reaction (PCR)-based nucleic acid analyses. Experts predict that such a device would enable researchers to develop rapid assays for cancer and other life-threatening diseases while a patient is in the doctor's office.

18 Jan 2009

Wyeth and Santaris Pharma to collaborate on RNA-based medicines

Wyeth Pharmaceuticals, a division of Wyeth, and Santaris Pharma have announced that the companies have entered into a worldwide strategic alliance to discover, develop and commercialize new medicines based on Santaris Pharma's proprietary Locked Nucleic Acid (LNA) drug platform, which allows specific targeting and regulation of microRNAs (miRNAs) and messenger RNAs (mRNAs) as a means to affect gene expression mediated by the targeted RNAs.

12 Jan 2009

Genomics in China

Ten years ago, the Chinese National Human Genome Center at Shanghai (South Center, hereafter) was established in the Zhangjiang HiTech Park of Pudong District in Shanghai.

7 Jan 2009

Why prostate cancer patients fail hormone deprivation therapy

The hormone deprivation therapy that prostate cancer patients often take gives them only a temporary fix, with tumors usually regaining their hold within a couple of years.

1 Jan 2009

What are protective effects of anti-ricin A-chain aptamer?

Ricin, a lectin from the castor bean plant Ricinus communis is considered one of the most potent plant toxins.

30 Dec 2008

Targeted nanoparticles boost platinum-based anticancer therapy

A research team from the Massachusetts Institute of Technology (MIT)-Harvard Center for Nanotechnology Excellence has custom-designed nanoparticles that can deliver the anticancer drug cisplatin specifically to prostate cancer cells.

20 Nov 2008

Santaris Pharma releases positive data on LNA-based survivin inhibitor

Santaris Pharma announced today that SPC3042, a RNA-based antisense oligonucleotide developed using the company's proprietary Locked Nucleic Acid (LNA) technology, potently blocks survivin, a key survival protein in cancer cells, in both in vitro and in vivo models of prostate cancer. Importantly, SPC3042 works synergistically with the anticancer drug paclitaxel (Taxol) in both model systems.

10 Nov 2008

FDA approves DNA test to measure hepatitis B viral load

The U.S. Food and Drug Administration today approved the first nucleic acid test for hepatitis B virus (HBV) that measures the amount of viral DNA (viral load) in a patient's blood. Assessing a patient's viral load provides health care professionals with a highly sensitive method for gauging the progress of antiviral therapy in patients with chronic HBV infections.

5 Sep 2008

FDA clears non-invasive test to help manage heart transplant patients

The U.S. Food and Drug Administration has announced it has cleared for marketing a non-invasive test that uses molecular expression techniques to assist doctors in managing heart transplant patients post-surgery for potential organ rejection.

27 Aug 2008

Roche acquires Mirus to advance RNAi delivery research

Roche (Basel) and Mirus Bio Corporation (Madison, WI, USA) announced today that they have entered into a definitive agreement under which Roche will acquire Mirus Bio Corporation, a privately-owned US company based in Madison, Wisconsin, that focuses on the discovery and development of innovative nucleic acid based technologies, including a proprietary RNAi (Ribonucleic Acid interference) delivery platform.

22 Jul 2008